Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

The City With the highest HIV/AIDS Rates in the US

We recently compiled a list of 20 Cities With the Highest HIV/AIDS Rates in the US and in this article, we will talk about the city with the highest HIV/AIDS rates in the US.

HIV Incidence and Prevalence in the United States

The government of the United States has set a goal to reduce the number of HIV infections by 75% by 2025 and 90% by 2030 as part of its Ending the HIV Epidemic in the US initiative. According to the Centers for Disease Control (CDC), there were approximately 32,100 estimated new infections in 2021 by transmission category in the US. Of these new infections 70% were reported among gay, bisexual, and male-to-male sexual contact, 22% were reported to be transmitted by heterosexual contact, and around 8% were transmitted among people who inject drugs. As per the Ending the HIV Epidemic Initiative, the government aims to curb the new infection number to 9,000 new infections by 2025, and to 3,000 by 2030.

In a regional analysis of the HIV incidence and prevalence within the United States, South America accounted for approximately 52% of the new HIV infections, followed by the Western and Mid-Western regions with 21% and 14% new infections during 2021. Northeast America accounted for the least new infections and reported only a 14% new infection rate during the same year. Analyzing the diagnosis trends among different races and ethnicities within America reveals that during 2021, 36% of African American gay or bisexual men were diagnosed with HIV infection, followed by Hispanic/Latino and white Americans with 33% and 25% diagnosis rates during 2021. Although the overall HIV diagnosis shows improvement as compared to 2017 figures, with HIV diagnosis among men and women going down by 15% and 11% respectively from 2017 to 2021. However, the government still needs to go a long way in reaching its 2025 target as according to the AtlasPlus data by CDC, around 37,601 people were diagnosed with HIV in 2022, up by 5.41% as compared to 2021 diagnosis figures.

An Overview of the Global HIV Drug Market

According to a report by Fortune Business Insights, the global HIV drug market was valued at $34.13 billion in 2023. The market is forecasted to grow at a compound annual growth rate of 6.2% to reach $58.24 billion by 2032. The viral infection is spreading around the world at a growing rate. According to the World Health Organization, an estimated 39.0 million people were living with the infection in 2022. However, on the bright side, the number of incidence of new HIV cases has reduced since 2010. As per the data, approximately 1.3 million people acquired HIV in 2022 as compared to 2.1 million people acquiring the virus in 2010. The increased awareness of the virus, prompt diagnosis, and demand for treatment medication are factors contributing to growth in the market.

Some of the leading pharmaceutical companies contributing to curbing and treating HIV infection include GSK plc (NYSE:GSK) and Merck & Co., Inc. (NYSE:MRK).

GSK plc (NYSE:GSK) is a leading pharmaceutical company based in the United Kingdom that researches and develops vaccines and other general medicines. The company through its subsidiaries operates in the United Kingdom, the United States, and internationally. On March 5 Reuters reported that GSK plc’s (NYSE:GSK) new HIV drug formula could support longer dosing intervals. The new formula can be potentially administered at least every 4 months as opposed to the previous requirement of 2-month dosing intervals. Moreover, the company has shifted its focus to long-acting treatments and prevention therapies.

Merck & Co., Inc. (NYSE:MRK) is another international healthcare company that operates through two segments; pharmaceuticals and animal health. On March 6, Merck & Co., Inc. (NYSE:MRK) along with Gilead Sciences, Inc. (NASDAQ:GILD) announced the results of a phase 2 clinical trial showing an oral once-weekly combination of the Regimen of Islatravir and Lenacapavir as a viable option to suppress the viral HIV infection. The combination was found to maintain a high rate (94.2%) of viral suppression rate. Gilead Sciences, Inc. (NASDAQ:GILD) is a leading innovator in developing treatment and conducting cure research for HIV.

A researcher at a microscope, inspecting cells to find the cure for BK virus.

Our Methodology

To compile the list of 20 cities with the highest HIV/AIDS Rates in the US, we used the US Center for Disease Control and Prevention’s Data Atlas for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention. From CDC’s Data Atlas, we selected the HIV and AIDS prevalence indicators, next, we selected Metropolitan Statistical Area (MSA) as our geography for the dataset and the latest year for which the data was available, in this case, it was 2022. Lastly, we selected the demographics for our dataset, which were ages 13 and older, all races/ethnicities, both sexes, and all transmission categories. With this, we had HIV and AIDS prevalence data of all major MSAs with a population of at least 500,000.

For this title we wanted to rank cities that had high rates of both HIV and AIDS, therefore, we averaged the rate per 100,000 of HIV and AIDS to rank the MSA’s.

Please note that the list contains major Metropolitan Statistical Areas (MSA), where each MSA contains multiple cities. The list is ranked in ascending order of the average rate of HIV and AIDS per 100,000. We have included the names of cities included in each MSA, in the list descriptions.

At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

The City With the highest HIV/AIDS Rates in the US

1. Fort Lauderdale-Pompano Beach-Sunrise, Florida

Average Rate of HIV and AIDS per 100,000: 929.3%

AIDS Rate per 100,000: 614%

HIV Rate per 100,000: 1244.6%

HIV Cases: 20,733

AIDS Cases: 10,228

The Fort Lauderdale-Pompano Beach-Sunrise Metropolitan Statistical Area in the state of Florida ranks as the city with the highest HIV/AIDS rates in the US. The area consists of Fort Lauderdale, Pompano Beach, and Sunrise cities which are located close to each other. The area had a combined average rate of HIV and AIDS prevalence of 929.3% per 100,000 people in 2022.

In addition, there were approximately 20,733 HIV cases and 10,228 AIDS cases in the area in 2022. All three major cities in the metro area are famous for their beaches and nightlife.

To learn about other cities with the highest rates of HIV/AIDS in the United States, you can checkout our detailed report on the 20 Cities with the Highest HIV/AIDS Rates in the US.

At Insider Monkey, we delve into a variety of topics, however, our expertise lies in identifying the top-performing stocks. Currently, Artificial Intelligence (AI) technology stands out as one of the most promising fields. If you are looking for an AI stock that is more promising than NVDA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 15 Biggest Asian Car Companies by Sales and 20 Countries With Highest Rates Of AIDS.

Disclosure: None. This article is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

 

Wall Street calls this $3 stock a “Melting Ice Cube.” They said the same thing about BTI before it returned 90%.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.